Switzerland's Engimmune Therapeutics scores €15M seed

Engimmune Therapeutics has received 15.5 million Swiss francs (about €15 million) in a round led by Pureos Bioventures and Novo Holdings. The startup is developing T-cell receptor-based therapies...

Related Keywords

Denmark ,Switzerland ,Swiss ,Pureos Bioventures ,Novo Holdings ,Engimmune Therapeutics ,